Peter Chatfield

720 citations
5 papers · 564 · 1 hit paper · h-index 4

Impact in

Papers in

Peter Chatfield

5 papers receiving 559 citations

Peter Chatfield's Hit Papers

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial 2019 · 539 citations
5390+2+4Years since publication100200300400500

Peers

Peter Chatfield
Comparison fields: 5 of 34
  • Oncology 281
  • Pulmonary and Respiratory Medicine 243
  • Cancer Research 54
  • Genetics 89
  • Radiology, Nuclear Medicine and Imaging 19
Replace Eduard O. Stakhovsky with:
Eduard O. Stakhovsky Ukraine
Icíar García-Carbonero Spain
Maialen Barrero Spain
Andrew J. Murtha Canada
J. E. Reid United States
Aglaia Schiza Sweden
Pingping Dai China
Chloe Baker United Kingdom
Sara Arce‐Gallego Spain
Marta Vaz Batista Portugal
Peter Chatfield relative to Eduard O. Stakhovsky Ukraine Eduard O. Stakhovsky's profile →
Citations per field
00.5×5×10×15×17.8×
Eduard O. Stakhovsky · 1×
Citations per year

Countries citing papers authored by Peter Chatfield

Since Specialization
Citations

This map shows the geographic impact of Peter Chatfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Chatfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Chatfield more than expected).

Fields of papers citing papers by Peter Chatfield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Chatfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Chatfield. The network helps show where Peter Chatfield may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Chatfield, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Chatfield Line = papers co-authored together Peter Chatfield links everyone, so they are left out of the graph.

All Works

5 of 5 papers shown
#Work
1
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Hit paper breakdown →
2019539
2 202112
3 20206
4 20235
5 20162

About Peter Chatfield

Peter Chatfield is a scholar working on Reproductive Medicine, Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging and Nuclear Energy and Engineering, having authored 5 papers that have together received 564 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (3 papers), Ovarian cancer diagnosis and treatment (2 papers), Prostate Cancer Diagnosis and Treatment (2 papers), PARP inhibition in cancer therapy (1 paper), Medical Imaging Techniques and Applications (1 paper) and Bone health and treatments (1 paper). The work is most often cited by research in Oncology (281 citations), Pulmonary and Respiratory Medicine (243 citations), Cancer Research (54 citations), Genetics (89 citations) and Radiology, Nuclear Medicine and Imaging (19 citations). Peter Chatfield has collaborated with scholars based in United Kingdom, New Zealand and Brazil. Frequent co-authors include Dow‐Mu Koh, John Nicholas Staffurth, Emma Hall, Anwar R. Padhani, Holly Tovey, Nina Tunariu, Sophie L. Perry, Chris C. Parker, Roberto Alonzi and Matthew Blackledge. Their work appears in journals such as The Lancet Oncology, Therapeutic Advances in Medical Oncology, Annals of Oncology, Clinical Genitourinary Cancer and JNCI Cancer Spectrum.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact